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Abstract
Background: Cerebral ischemia generates neuroinflammation that can induce neural cell death. This cohort study
assessed whether Fas-ligand (FasL) and interleukin (IL)-6 levels in the cerebrospinal fluid (CSF) after hypoxic-ischemic
encephalopathy (HIE) can serve as biomarkers of hypoxic brain injury in neonates.
Methods: Term infants (> 37-week gestational age) who were admitted to the neonatal intensive care unit of Karolinska
University Hospital in years 2002 to 2004 with perinatal asphyxia were enrolled prospectively. Control infants without
brain pathology underwent lumbar puncture for suspected infection. FasL and IL-6 levels were measured in the CSF, by
enzyme-linked immunosorbent assays. All patients underwent neurological assessment at 18 months. HIE was classified as
mild, moderate, or severe (HIE I–III). Adverse neurological outcome at 18 months was defined as a mental developmental
index < 85, deafness, blindness, cerebral palsy, or seizure disorder.
Results: Of the 44 HIE patients, 14, 16, and 14 had HIE-I, HIE-II, and HIE-III, respectively. HIE-II and HIE-III patients had higher
FasL and IL-6 levels than HIE-I patients and the 20 controls (all p < 0.0001). Patients with adverse outcomes had higher
FasL and IL-6 levels than patients with normal outcomes and controls (both p< 0.0001). On receiver-operator curve analyses,
FasL and IL-6 (alone and together) were highly predictive of HIE grade and outcome (areas under the curve range 0.86–0.94)
and showed high sensitivity (66.7–100%). These biomarkers performed better than cord blood pH (areas under the curve:
HIE grade = 0.80, adverse outcomes = 0.86).
Conclusion: CSF biomarkers FasL and IL-6 predicted severity of encephalopathy and long-term outcomes in post-
asphyxiated infants better than a standard biomarker.
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Key notes
 Following birth asphyxia, FasL and IL-6 are released
into the CSF.
 FasL and IL-6 levels in CSF correlate with HIE grade
and long-term clinical outcome of post-asphyxiated
patients.
 Both alone and together, FasL and IL-6, accurately
predict the degree of hypoxic neonatal brain injury
and long-term outcomes with high sensitivity.
Background
Hypoxic-ischemic encephalopathy (HIE) is characterized
by clinical and laboratory signs of brain damage after peri-
natal asphyxia. It has an incidence of 2.5 per 1000 live
births and associates with high rates of morbidity and
mortality [1]. Cerebral hypoxic ischemia induces a strong
neuroinflammatory response. After the primary insult, a
cascade of events evolves to delayed cellular death that ex-
tends over several days. Apoptosis features particularly
prominently in this phenomenon [2]. This biphasic pat-
tern of neuronal death represents a window of opportun-
ity for treatment such as therapeutic hypothermia, which
is today the standard treatment for neonates with HIE [3].
However, while hypothermia is an effective treatment
strategy, there is still an urgent need for additional novel
interventions that protect the neurons from secondary
damage and improve the clinical outcome.
The pathophysiology of HIE is not fully understood, but
several studies suggest that the extrinsic apoptotic path-
way involving the transmembrane death receptor Fas
(CD95/Apo-1) and its natural ligand Fas-ligand (FasL)
plays a central role [2, 4]. This is supported by several
other studies. First, Fas receptor expression is upregulated
in the brain during hypoxia, and mice that lack functional
Fas receptors are protected from HIE brain injury [5]. Sec-
ond, after head trauma in adults, Fas receptor and FasL
are expressed in the central nervous system [6]. Third,
preterm infants with post-hemorrhagic hydrocephalus
have increased levels of soluble Fas receptor (sFas) in the
cerebrospinal fluid (CSF), and the concentration correlates
with the extent of white matter damage [7].
Evidence from experimental research indicates that in-
flammation and the associated production of inflammatory
mediators play a significant role in the pathophysiology of
brain ischemia [8]. Interleukin-6 (IL-6) is particularly inter-
esting because its production in the post-hypoxic inflam-
matory cascade has been reported to have both neurotoxic
and neuroprotective effects [9, 10]. The neurotoxicity of
IL-6 is demonstrated by the fact that, in infants with HIE,
increased IL-6 levels, in both serum and CSF, correlate
positively with brain injury severity and the clinical out-
come [11, 12]. The neuroprotective effect of IL-6 is exem-
plified by its ability to protect cerebral granular neurons
from N-methyl-D-aspartate-induced excitotoxicity in vitro
(9) and the fact that IL-6 injections into the brain after is-
chemia reduce ischemic brain injury (10). These opposing
roles of IL-6 may reflect different functions at different
stages of brain ischemia damage: specifically, it may medi-
ate destructive inflammation during the acute phase while
enhancing regeneration of the nerves in the subacute and
prolonged phases [10, 13].
We hypothesized that FasL and IL-6 are upregulated
in CSF samples from human infants after perinatal as-
phyxia and that they may correlate positively with the
severity of HIE and the clinical outcome of patients. To
address this, infants with HIE were compared with con-
trol infants with suspected infection in terms of FasL
and IL-6 levels in the CSF.
Methods
Ethics
This study was performed in accordance with the tenets
of the declaration of Helsinki 1975 and its revision in
1983 and European Community guidelines. The regional
ethics committees at the Karolinska Institutet and the
Stockholm County approved the study (Dnr 98-246,
2003-174, 2011/1891-31). Informed written consent was
obtained from the parents of the enrolled patients.
Patient population
All consecutive term infants (> 37-week gestational age)
who were admitted to the neonatal intensive care unit of
Karolinska University Hospital in Stockholm between
October 2000 and September 2004 were enrolled pro-
spectively into the study if they underwent clinically in-
dicated lumbar puncture (LP), had experienced perinatal
asphyxia, and met the following criteria:
1. Signs of fetal distress, as indicated by the
cardiotocographic pattern of late decelerations, lack
of variability, or bradycardia; meconium staining of
amniotic fluid; and scalp pH < 7.1 or blood lactate
levels > 4.8 mM.
2. Postnatal stress, as indicated by Apgar score < 6 at
5 min or pH ≤ 7.00/base deficit ≥ 16 mEq in the
umbilical arterial/first postnatal blood from the infant,
plus need for neonatal resuscitation for > 3 min.
3. Neurological signs of encephalopathy within 6 h of
birth according to the NICHD classification for
modified Sarnat staging [14].
Infants with congenital malformations, chromosomal
abnormalities, metabolic disease, and evidence of intra-
uterine/perinatal infections with confirmed meningitis or
with encephalopathy unrelated to birth asphyxia were ex-
cluded from the study. The control group were full-term
infants who were born in the hospital in the same period
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and were assayed for suspected infection but whose blood
and CSF were found to be negative after culture; more-
over, none had any findings that were suggestive of path-
ology in the brain.
Clinical assessments
All infants underwent neurological assessment shortly
after birth before they were enrolled in the study. The
assessment was then repeated approximately 12, 36, and
72 h and 7 days after birth and at discharge from the
NICU. All assessments were conducted by the same
neonatologist. HIE was classified as mild (HIE-I), moder-
ate (HIE-II), or severe (HIE-III) according to the criteria
of Sarnat and Sarnat [14].
All patients were treated under normothermic condi-
tions and received standard treatment at the time of re-
cruitment. This included fluid restriction, ionotropic
support, and mechanical ventilation when needed as well
as medical treatment for seizure activity. Continuous
amplitude-integrated EEG was used to assess brain activ-
ity and suspected seizures. Given the clinical routine at
the time of patient recruitment, all patients with moder-
ate to severe encephalopathy underwent computed tom-
ography (CT) brain scans and, in some cases, magnetic
resonance imaging (MRI) on the third to fifth day of life.
All surviving patients were monitored with full neuro-
logical examinations at 3, 6, and 18 months of age that
were conducted by an experienced neuropediatrician. The
neurodevelopment of the patients who exhibited abnor-
mal neurodevelopment or neurological signs on the exam-
ination at 18 months was assessed using the Bayley Scales
of Infant and Toddler Development-II (BSID-II) [15],
which was the Bayley version at that time. Outcome at
18 months was defined as normal outcome, adverse
neurological outcome, or death. Adverse neurological
outcome at 18 months was defined as a mental develop-
mental index < 85, deafness, blindness, cerebral palsy, or
seizure disorder.
The Hammersmith Infant Neurological Examination
was performed on all control infants by an experienced
neonatologist to get a standardized neurological assess-
ment before discharge from NICU. Information on the
outcome of the control infants at 18 months was gath-
ered from outpatient pediatric care centers. All had nor-
mal neurological examination and none exhibited any
abnormal neurological signs or history. None of the CSF
samples from the controls showed indications of infec-
tion, and blood cultures were negative as well.
CSF analysis
CSF was collected from all patients within the first 3 days
of life. CSF samples were stored at − 80 °C until ana-
lyzed. The CSF concentrations of IL-6, FasL, IL-6 recep-
tor (IL-6R), and the soluble form of the Fas receptor
(sFas) were measured by enzyme-linked immunosorbent
assay (Diaclone Research, Besançon, France). The detec-
tion limits were 2 pg/mL (IL-6 and IL-6R), 12 pg/mL
(FasL), and 47 pg/mL (sFas). The results were normal-
ized against total protein content, which was measured
using the bicinchoninic acid assay (Pierce, Rockford, IL,
USA). In some patients and controls, competition en-
zyme immunoassays were used to measure prostaglan-
din E2 metabolite (PGEM). The assay was performed
according to a commercial standardized protocol (Cay-
man Chemicals, Ann Arbor, MI, USA). Some of the
PGEM data have been presented previously [16].
Statistical analyses
All clinical variables are presented as median (interquartile
range). In terms of continuous variables, two independent
groups were compared using the Mann-Whitney U test,
while three independent groups were compared using the
Kruskal-Wallis test with Dunn’s multiple comparison post
hoc test. Two related groups were compared using the Wil-
coxon matched-pairs signed-rank test. Three related groups
were compared using the Friedman test with Dunn’s mul-
tiple comparison post hoc test. Correlations between vari-
ables were determined using the Spearman rank correlation
test. In terms of categorical variables, the groups were com-
pared using the chi-squared test. A graphical plot, namely,
the receiver-operator characteristic (ROC) curve, was used
to evaluate the ability of biomarkers to classify disease sta-
tus and outcome. The maximum effectiveness of the bio-
markers was evaluated using the Youdan Index. To
evaluate the potential advantage of combining the FasL and
IL-6 concentrations to identify degree of HIE and final out-
come, we ranked the values of IL-6 and FasL. The rank
sum was then subjected to ROC analysis.
All statistical tests were two-sided, and p values less than
0.05 were considered to indicate statistical significance.
Results
Patient characteristics at birth
In total, 46 term infants with HIE were initially enrolled
into the study. Two infants with HIE who met the study
eligibility criteria were then excluded because they were
confirmed to have meningitis and suspected metabolic
disease, respectively. Thus, 44 patients with HIE were fi-
nally included in the study. Twenty control infants with-
out brain pathology who underwent LP for suspected
infection but were then found to lack blood or CSF in-
fection served as the control group.
The characteristics of the patient and control groups are
summarized in Table 1. The two groups did not differ in
terms of gestational age or birth weight. However, as ex-
pected, the HIE patients had significantly lower Apgar
scores and blood gas values of pH than the control infants
(both p < 0.001). Of the 44 patients, 14 (31.8%), 16 (36.4%),
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and 14 (31.8%) were classified according to the classifica-
tion system of Sarnat and Sarnat as having HIE-I, HIE-II,
and HIE-III in the first days of life, respectively. The three
HIE groups did not differ in terms of gestational age or
birth weight.
Outcomes at 18 months
All control infants had normal outcomes at 18 months.
The outcomes of the HIE patients at 18 months are sum-
marized in Table 2. Thus, all 14 infants with HIE-I had a
normal neurological examination at discharge from the
NICU and a normal neurological outcome at 18 months.
Of the 16 HIE-II infants, six had no neurological signs at
discharge and were normal at the neurological assessment
at 18 months. Two HIE-II patients had normal assessment
at discharge but adverse neurological signs at 18 months.
The remaining eight HIE-II patients had both neurological
signs at discharge and abnormal neurological outcomes at
18 months. Thus, 10 patients with HIE-II had adverse
neurological outcomes at 18 months. Of the 14 patients
with HIE-III, eight died within the first 2 weeks of life of
multiorgan failure due to asphyxia. The remaining six
HIE-III patients all had both neurological signs at discharge
and abnormal neurological outcomes at 18 months.
Association between early CT/MRI findings and outcomes
at 18 months
All 30 patients with HIE-II and HIE-III underwent CT
and in some cases MRI on the third to fifth day after
birth. All HIE-III infants and 8 of the 10 HIE-II infants
who had an adverse neurological outcome at 18 months
showed signs of edema on CT. In addition, three infants
with HIE-II who had a normal neurological outcome at
18 months had signs of edema on CT. Four of the
HIE-III infants also underwent MRI: the other patients
did not undergo MRI because it was not routinely per-
formed at the time of recruitment. All four HIE-III pa-
tients showed profound ischemic changes in the basal
ganglia and thalami. Of these, two died in the neonatal
period and one survived with adverse neurological out-
comes at 18 months.
FasL and IL-6 levels in the CSF
In total, 76 CSF samples were gathered from the 44 pa-
tients and the 20 controls. One sample was obtained
from 32 patients and 20 controls, and two samples were
obtained from the remaining 12 patients. In the patients
who underwent a single LP, the procedure was per-
formed at a median of 22.5 (interquartile range, 15–42)
h after birth and for controls 26 (13.5–48) h after birth.
In the patients who underwent two LPs, the procedures
were performed 14 (8–23) and 72 (60–111) h after birth,
respectively. In the latter patients, the average FasL and
IL-6 levels in the two CSF samples were used in the fol-
lowing statistical analyses.
The HIE patients had significantly higher FasL levels
in the CSF (median, 62; interquartile range, 16–119 pg/
mL) than the normal control infants (0, 0–0 pg/mL) (p
< 0.0001). The patients with HIE-II (75.7, 43.7–129.4 pg/
mL) and HIE-III (105.2, 28.5–168.6 pg/mL) also had sig-
nificantly higher FasL levels than the patients with HIE-I
(10.6, 0–41.6 pg/mL) and the controls (all p < 0.0001)
Table 1 Clinical data of asphyxiated newborns and newborn nonasphyxiated controls
Controls HIE-I HIE-II HIE-III
Number of patients 20 14 16 14
Gestational age (week)a 39.5 (38.8 to 41.7) 41.1 (37.4 to 41.3) 40.1 (38.6 to 40.3) 39.0 (37.2 to 40.4)
Birth weight (g)a 3614 (2820 to 4570) 3500 (3240 to 4050) 3650 (3325 to 3975) 3310 (3225 to 3595)
Gender (female:male)a 10:10 7:7 7:9 8:6
1-min Apgar score** 9 (7 to 9) 2 (1 to 3) 1.5 (1 to 4) 1 (1 to 2)
5-min Apgar score** 10 (8 to 10) 5 (4 to 6) 3.5 (3 to 6) 3 (0 to 4)
10-min Apgar score** 10 (10 to 10) 6.5 (6 to 7) 5 (3 to 7) 4.5 (2 to 6)
Arterial pH** 7.40 (7.13 to 7.40) 7.00 (6.90 to 7.10) 7.00 (6.80 to 7.20) 6.90 (6.70 to 7.10)
BEa − 2.5 (− 18.5 to − 0) − 17.0 (− 19.3 to − 9.4) − 24.0 (− 27.0 to − 17.0) − 20.0 (− 25.0 to − 14.3)
Maternal infectiona 0 2 2 2
Data are expressed as median (IQR)
aNot statistically significant
**p < 0.0001
Table 2 Final outcome of asphyxiated newborns and newborn
nonasphyxiated controls
Controls HIE-I HIE-II HIE-III
Number of patients 20 14 16 14
Outcome
Normal 20 14 6 0
Adversea 0 0 10 6
Death 0 0 0 8
HIE Hypoxic ischemic encephalopathy
aAdverse neurological outcome, including neurodevelopmental delay with
developmental scores < 85 on BSID-III, deafness or blindness, and cerebral
palsy or seizure disorder
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(Fig. 1a). Difference was not found between the HIE-II
and HIE-III groups.
The HIE group also had significantly higher IL-6 levels
in the CSF (77, 9–214 pg/mL) than the control infants (0,
0–12.4 pg/mL) (p < 0.001). The patients with HIE-II (37.7,
11.4–283 pg/mL) and HIE-III (179, 104–368 pg/mL) also
had higher IL-6 levels than the patients with HIE-I (6.75,
0–50.2 pg/mL) and the controls (all p < 0.0001) (Fig. 1b).
Correlations between FasL and IL-6 levels with both HIE
severity and outcome at 18 months
We assessed the relationship between FasL and IL-6 in
the CSF and clinical outcomes. First, since Apgar score at
10 min predicts the neurological outcomes of infants with
HIE [17], we assessed its relationship with the FasL and
IL-6 levels in the CSF shortly after birth. FasL and IL-6
both correlated inversely with Apgar scores at 10 min
(rs = − 0.577 and − 0.622, respectively) (both p < 0.0001)
(Additional file 1: Figure S1).
Second, correlation analyses showed that the CSF con-
centrations of FasL and IL-6 also correlated positively
with the HIE grade (rs = 0.6898 and 0.6864, respectively)
(both p < 0.0001). Third, we assessed the relationship be-
tween clinical outcome at 18 months (normal or adverse
neurological outcome or death) and the FasL and IL-6
levels in the CSF.
FasL
The patients with poor outcomes (i.e., adverse neuro-
logical outcome at 18 months or death) had higher FasL
levels (105; 36.6–166 pg/mL) than the patients with fa-
vorable outcomes (10.6, 0–37.1 pg/mL) or the control
infants (0, 0–0 pg/mL) (both p < 0.0001) (Fig. 2a). It
should be noted, however, that the patients with adverse
outcomes varied markedly in their FasL levels. Indeed,
two of the patients who died had FasL levels below the
detection limit. The patients who survived with adverse
neurological outcomes did not differ from the patients
who died in terms of CSF FasL levels. Correlation ana-
lysis showed that the CSF concentrations of FasL corre-
lated positively with poor 18-month clinical outcomes
(rs = 0.7017) (p < 0.0001).
IL-6
The patients with poor outcomes had significantly higher
IL-6 levels (162, 35.6–264 pg/mL) than the patients with
normal outcomes (9.35, 0–40.8 pg/mL) or the control in-
fants (0, 0–5.35 pg/mL) (both p < 0.0001) (Fig. 2b). The
patients who survived with adverse neurological outcome
did not differ from the patients who died in terms of CSF
IL-6 levels. Correlation analyses showed that the CSF con-
centrations of IL-6 correlated positively with poor
18-month clinical outcomes (rs = 0.7017) (p < 0.0001).
Time-dependent trends in FasL and IL-6 levels in the CSF
Twelve patients provided a CSF sample at two different
time points. All had HIE-II or HIE-III. Nine had adverse
outcomes at 18 months. The remaining three had nor-
mal outcomes. In all patients, the FasL levels were
higher in the second sample (p = 0.0025) (Fig. 3a).
In relation to IL-6, the levels were lower in the second
sample in all but three cases (p = 0.0522) (Fig. 3b). In
these three cases, the patients had low IL-6 levels in the
first sample. Two of these three patients had normal
outcomes. The nine patients who exhibited lower IL-6
levels in the second sample all had adverse 18-month
outcomes. Thus, over time, FasL and IL-6 levels in the
CSF rose and fell, respectively.
Fig. 1 Fas-ligand (FasL) and interleukin-6 (IL-6) levels in the cerebrospinal fluid (CSF) correlate with the degree of hypoxic-ischemic encephalopathy
(HIE), which was classified as mild (HIE-I, n = 14), moderate (HIE-II, n = 16), or severe (HIE-III, n = 14). The controls were infants with no signs of HIE
(n = 20). FasL levels (pg/mL) (a) and IL-6 levels (pg/mL) (b) were higher in the patients with HIE-III and HIE-II than in the patients with
HIE-I and the controls. ***p < 0.0001
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FasL and IL-6 levels in the CSF are indicators for HIE
severity
ROC curves for FasL and IL-6 levels in relation to HIE
were generated, and the areas under the ROC curves
(AUCs) were estimated. These analyses showed that
FasL and IL-6 predicted HIE with AUC values of 0.89
and 0.87, respectively (Fig. 4a, b). The Youdan Indices
were then calculated: thus, the FasL cutoff of > 24 pg/mL
predicted HIE with the highest sensitivity (90%) and
specificity (82.4%), and the IL-6 cutoff of > 77 pg/mL
predicted HIE with the highest sensitivity (66.7%) and
specificity (94.1%).
Combining the IL-6 and FasL using rank order ren-
dered a positive predictive value of 0.94. The sensitivity
was 86.7% and specificity 91.2% in relation to degree of
HIE (Fig. 4c). Notably, using the two cutoff values to-
gether also predicted HIE grade II–III with a sensitivity
of 100% and a specificity of 79.4%, Table 3.
To determine how well FasL and IL-6 predict HIE, we
also assessed the ability of cord blood pH, which is the
established biomarker for perinatal asphyxia, to predict
HIE. Cord blood pH predicted HIE with an AUC of
0.80. Cord blood pH < 6.85 predicted HIE with a sensi-
tivity of 66.7% and a specificity of 80.0% (data not
Fig. 3 Kinetics of Fas-ligand (FasL) and interleukin-6 (IL-6) in the cerebrospinal fluid (CSF) from the 12 patients who provided a sample at two
different time points. Lines indicate the samples from the same patient. a All patients had higher FasL levels in the later samples. b In 9 of the 12

















Fig. 2 Fas-ligand (FasL) and interleukin-6 (IL-6) levels in the cerebrospinal fluid (CSF) correlate with the long-term outcomes after perinatal
asphyxia. Adverse outcome is defined as adverse neurological outcome at the 18-month assessment or death. FasL levels (pg/mL) (a) and IL-6
(pg/mL) levels (b) were higher in patients with an adverse outcome (n = 24) than in patients with a normal outcome (n = 20) and the controls
(n = 20). ***p < 0.0001
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shown). Thus, FasL and IL-6 alone and together pre-
dicted the degree of HIE better than this well-known
standard marker of perinatal asphyxia.
Ability of FasL and IL-6 levels in the CSF to predict
adverse outcomes at 18 months
ROC curves for FasL and IL-6 levels in relation to the
outcomes at 18 months were generated, and the AUCs
were estimated. These analyses showed that FasL and
IL-6 predicted adverse 18-month outcomes (i.e., adverse
neurological outcome or death) with AUCs of 0.86 and
0.90, respectively (Fig. 5a, b). The Youdan Indices were
calculated: the FasL cutoff of > 45 pg/mL predicted
adverse outcomes with a sensitivity of 79.2% and a
specificity of 82.5%, and the IL-6 cutoff of > 77 pg/mL
predicted adverse outcomes with a sensitivity of 79.2%
and a specificity of 92.5%.
Combining the IL-6 and FasL using rank order ren-
dered a positive predictive value of 0.94. The sensitivity
was 95.8% and specificity 85.7% in relation to outcome
(Fig. 5c). Notably, using the two cutoff values together
also predicted adverse outcome with a sensitivity of
100% and a specificity of 80.0% (Table 3).
By contrast, cord blood pH predicted adverse out-
comes with an AUC of 0.86. Cord blood pH < 6.85 pre-
dicted adverse outcomes with a sensitivity of 66.7% and
a specificity of 93.6% (data not shown). Thus, FasL and
IL-6 alone and together predicted adverse outcomes at
Fig. 4 Receiver-operator characteristic (ROC) curve of Fas-ligand (FasL) and interleukin-6 (IL-6) in relation to hypoxic-ischemic encephalopathy
(HIE) grade. Control and HIE I versus HIE grade II–III. a The AUC for FasL was 0.89. The FasL cutoff value of 24 pg/mL (dashed lines) predicted HIE
grade with a sensitivity of 90.0% and a specificity of 82.4%. b The AUC for IL-6 was 0.87. At the cutoff value of 77 pg/mL (dashed lines), IL-6
predicted HIE grade with a sensitivity of 66.7% and a specificity of 94.1%. c Using a combination of ranks for IL-6 and Fas-L, the sensitivity was
86.7% and specificity 91.2% in relation to degree of HIE. The sum for ranking of IL-6 and Fas-L was used for the evaluation. The AUC for the sum
for ranking was 0.94
Table 3 Sensitivity and specificity of outcome of asphyxiated newborns and newborn nonasphyxiated controls
HIE grade Outcome
IL-6 > 77 pg/mL FasL > 24 pg/mL IL-6 > 77 pg/mL and/or
FasL > 24 pg/mL
IL-6 > 77 pg/mL FasL > 45 pg/mL IL6 > 77 pg/mL and/or
FasL > 45 pg/mL
True positive 20 27 30 19 19 24
True negative 32 28 27 37 33 32
False positive 2 6 7 3 7 8
False negative 10 3 0 5 5 0
Specificity (%) 94.1 82.4 79.4 92.5 82.5 80.0
Sensitivity (%) 66.7 90.0 100.0 79.2 79.2 100.0
Accuracy (%) 81.3 85.9 89.1 87.5 81.3 87.5
Negative predictive
values (%)
76.2 90.3 100.0 88.1 86.8 100.0
Positive predictive
values (%)
90.9 81.8 81.1 86.4 73.1 75.0
HIE Hypoxic ischemic encephalopathy
aDeath or Adverse neurological outcome, including delayed neurodevelopment with mental developmental index (MDI) < 85, deafness or blindness, and cerebral
palsy or seizure disorder
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18 months better than this well-known standard marker
of perinatal asphyxia.
Soluble forms of FasL and IL-6 receptors in the CSF
Our findings prompted us to determine the levels of the
soluble forms of the receptors for FasL and IL-6. sFas
levels were measured in 26 patient samples and 20 control
samples. Seven patient samples had high sFas levels (ran-
ging from 355 to 1160 pg/mL), and all but one of these
patients had an adverse outcome at 18 months. The me-
dian sFas concentration of the patients was 441 pg/mL. By
contrast, sFas levels in all control infant samples were
below the limits of detection (Additional file 2: Table S1).
All patient CSF samples had significant amounts (i.e.,
above the upper limit of the test) of IL-6R. By contrast,
the IL-6R levels in all control infant samples were below
the limits of detection (data not shown).
Relationship between PGEM and IL-6 levels in the CSF
We reported previously that increased levels of PGEM
in the CSF correlate with 18-month clinical outcomes of
infants with HIE [16]. We measured the PGEM levels in
the CSF of 25 patients and nine controls in this study.
We found that the PGEM levels correlated significantly
with the IL-6 levels in the CSF (p = 0.0009) (Fig. 6). In
contrast, no correlation was found between the FasL
levels and the PGEM levels.
The inclusion of PGEM data in addition to IL-6 and
FasL data in Table 3 increased neither specificity nor
sensitivity for identification of patients with HIE grade
II–III or poor outcome.
Discussion
The main findings of this study were that post-asphyxiated
neonates had elevated levels of the inflammatory mediators
IL-6 and FasL in their CSF shortly after birth. Since the
levels of both molecules correlated positively with HIE
grade and poor 18-month clinical outcome, they may be
useful as biomarkers for the severity of hypoxic brain injury
and for predicting the long-term outcome after perinatal
asphyxia.
Animal and human studies show that a variety of cyto-
kines are expressed in the brain in cerebral ischemia and
that the cytokine profile associates significantly with the
severity of ischemic brain damage [18, 19]. Moreover, it
has been suggested that cytokines can either induce or
ameliorate ischemic brain injury and that these opposing
Fig. 5 Receiver-operator characteristic (ROC) curve of Fas-ligand (FasL) and interleukin-6 (IL-6) in relation to adverse outcome. Adverse outcome is
defined as adverse neurological outcome at the 18-month assessment or death. a The AUC for FasL was 0.86. The FasL cutoff value of 45 pg/mL
(dashed lines) predicted adverse outcomes with a sensitivity of 79.2% and a specificity of 82.5%. b The AUC for IL-6 was 0.90. The IL-6 cutoff value
of 77 pg/mL (dashed lines) predicted adverse outcomes with a sensitivity of 79.2% and a specificity of 92.5%. c Using a combination of ranks for
IL-6 and Fas-L, the sensitivity was 95.8% and specificity 85.7% in relation to outcome. The sum for ranking of IL-6 and Fas-L was used for the
evaluation. The AUC for the sum for ranking was 0.94
Fig. 6 Levels of interleukin-6 (IL-6) and the prostaglandin E2 metabolite
(PGEM) in the cerebrospinal fluid (CSF) correlate (p= 0.0009). rs Spearman
rank correlation coefficient
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functions depend on both the phase of the neural cell
damage and the severity of the insult [10]. These time-
and severity-dependent changes in cytokine levels mean
that the levels of a given cytokine in a CSF sample will
only provide a snapshot of an ongoing process; it is often
difficult to know when exactly a cytokine is promoting is-
chemic brain injury or acting protectively. This is exempli-
fied by several studies on the role of IL-6 in therapeutic
hypothermia, which is thought to be neuroprotective be-
cause it has anti-inflammatory properties [20]. When Jen-
kins and colleagues serially measured cytokines every 12 h
for 4 days after the birth, they found that HIE patients
who underwent hypothermia treatment had higher serum
IL-6 levels at all time points than HIE infants who were
treated under normothermic conditions [13]. Moreover,
the IL-6 levels in the hypothermia-treated group were bi-
phasic while the IL-6 levels in the normothermic patients
tended to decline over time. Significantly, while high IL-6
levels early after the insult, in both groups, are associated
with adverse 18-month outcomes, a secondary peak of
IL-6 is associated with better outcomes [13, 21]. This
suggests that IL-6 may have biphasic roles in the patho-
genesis of hypoxic brain injury: it induces inflammation
and injury early after the insult but then contributes to
cytokine-mediated repair at later time points [21, 22].
In the present study, the patients did not receive
therapeutic hypothermia because it was not an estab-
lished therapy for HIE at the time of recruitment. We
found that, in the 12 patients who underwent LP at two
separate time points after birth, the IL-6 levels were
lower in the second sample in all but three cases
(Fig. 3b). This is consistent with previous observations,
regarding normothermic patients where serum IL-6
levels after birth asphyxia were characterized in [13, 21].
All patients in the present study who exhibited a drop in
IL-6 levels had adverse 18-month outcomes. Two of the
three patients who had increased IL-6 levels between
first and second LP had normal outcomes. However,
those patients had low IL-6 levels in the first sample and
the rise was small (9.9 pg/mL, 9–10.5 in LP1 and
63.3 pg/mL, 59.5–67 in LP2) (Fig. 3b).
It should be noted that we measured IL-6 levels in
the CSF, whereas several studies measure the serum
IL-6 levels, e.g., [13, 21]. The fact that our findings
closely resemble those of normothermic patients [13]
probably reflects the fact that the serum and CSF
concentrations of IL-6 in term infants with asphyxia
correlate [23].
A systematic review of potential brain injury bio-
markers identified serum IL-6 as one of the few inde-
pendent predictors of adverse outcome in survivors of
HIE [24]. However, CSF IL-6 may be a better predictor
of adverse outcomes because local cytokine profiles are
often poorly reflected in the plasma: this is because the
plasma levels can also be shaped by secondary reactions
to the injury [25, 26].
Intracellular cytokine levels, which closely reflect cyto-
kine production at a cellular level and show more stable
kinetics in time, have recently been analyzed in term in-
fants requiring systemic hypothermia after perinatal as-
phyxia [27]. In that study, intracellular IL-6 levels in
CD4+ peripheral blood mononuclear cells peaked at
24 h post-asphyxia. However, IL-6 levels exhibited a
large variability and did not differ between the two pa-
tient groups moderate (n = 17) and severe (n = 11) as-
phyxia. Thus, IL-6 plays an important role in the initial
inflammatory response, but determination of CSF levels
of IL-6 might better predict adverse outcomes in survi-
vors of HIE [28].
IL-6 initiates a signal transduction cascade by binding
to specific IL-6 membrane receptors (IL-6R). Apoptosis
associates with the shedding of membrane components,
including IL-6R, which then facilitates IL-6 signaling in
neighboring cells [29]. While most brain cells are not re-
sponsive to IL-6 alone, they can be stimulated by IL-6
bound to a soluble form of IL-6 receptor in a process
called trans-signal activation [30]. The present study
showed that the HIE patients had high concentrations of
IL-6R in all samples whereas the IL-6R levels in all con-
trol infants were below the detection limit. It is possible
that the high levels of IL-6R in the CSF of the HIE pa-
tients reflect an apoptotic process that is taking place in
the brain at the time the samples were gathered. Unfor-
tunately, the CSF samples were limited in volume, which
meant that the IL-6R measurements were not accurate
enough to assess the relationship between IL-6R levels
and long-term outcomes.
This study showed that FasL, which plays a key role in
apoptosis, also correlated positively with both the HIE
grade (Fig. 1a) and the adverse long-term outcomes
(Fig. 2a) in HIE patients. Experimental studies suggest
that hypothermia blocks the Fas-mediated intrinsic and
extrinsic apoptosis pathways [31, 32]; however, clinical
studies are needed to confirm this. The naturally occur-
ring soluble form of Fas receptor, sFas, prevents cell
ligation with FasL, and this blocking of FasL inhibits
neuronal cell apoptosis in experimental brain ischemia
[33]. sFas has been found in the CSF from neonates with
hydrocephalus [34], but in that study, FasL was not de-
tected. We found that, while none of the control infants
had sFas in their CSF, 7 of 26 HIE patients had high
levels and that all but one of these had adverse outcomes
at 18 months. This suggests that CSF sFas may not actu-
ally protect HIE infants from FasL-induced apoptosis
and the consequent poor outcomes.
Prostaglandin E2 (PGE2) is another important medi-
ator of neuroinflammation [35]. PGE2 and its derivative
PGEM rapidly increase during hypoxia [36]. We found
Leifsdottir et al. Journal of Neuroinflammation  (2018) 15:223 Page 9 of 11
that IL-6 levels in the CSF correlated positively with the
PGEM levels in the CSF (Fig. 6). However, since only a
subgroup of the patient cohort was examined for both
PGEM and IL-6, and we have already established that in-
creased levels of PGEM in CSF correlate positively with
the clinical outcome of infants with HIE [16], we thus
focused our further analyses on FasL and IL-6.
Our ROC curve analyses showed that IL-6 and FasL
in the CSF may be useful as additional tools for eval-
uating the severity of hypoxic-ischemic encephalopathy
in post-asphyxiated infants and for predicting the
long-term outcomes. First, this study showed that FasL
(AUC = 0.89) and IL-6 (AUC = 0.87) predict HIE grade
even better than cord blood pH (AUC = 0.80). When
FasL and IL-6 were combined, they predicted HIE
grade particularly well (AUC = 0.94). Second, FasL
(AUC = 0.90) and IL-6 (AUC = 0.86) predicted adverse
outcomes better than cord blood pH (0.86). This per-
formance was even better when FasL and IL-6 were
combined (AUC = 0.94).
Notably, this novel and unprecedented results of pre-
diction for HIE and long-term outcome, using CSF bio-
markers, could help guide treatment decisions. Thus,
prospective studies concerning the benefits of CSF cyto-
kine measurements also in hypothermic treated patients
would indeed be of value.
The main limitation of this study was the time lapse be-
tween patient recruitment and the presentation of the re-
sults. However, the fact that the patients were recruited
before hypothermia became the standard treatment for
HIE could be considered an advantage because it allowed
us to compare our FasL and IL-6 findings in that setting
with the findings of other studies, which were all con-
ducted after therapeutic hypothermia was introduced as a
standard treatment. Another limitation is that, while an
experienced pediatric neurologist performed the routine
clinical follow-up on all post-asphyxiated children at the
Karolinska Hospital at that time, only the patients with
neurological symptoms or signs at 18 months were
assessed with the Bayley developmental evaluation assess-
ment: the patients without signs did not undergo BSID-II
scoring. Further studies on the diagnostic benefits of mon-
itoring FasL and IL-6, with or without other biomarkers,
in newborn infants with HIE who are treated with thera-
peutic hypothermia are warranted. Further studies on
these biomarkers may also shed more light on the path-
ology of brain damage and determine whether targeting
them may be of therapeutic benefit.
Conclusion
IL-6 and FasL are released into the CSF during birth as-
phyxia. These biomarkers support the clinical diagnosis
of HIE degree, thus correlating to the degree of brain in-
jury, and are useful for predicting the long-term clinical
outcome. Thus, they may aid the early decision-making
regarding treatment of asphyxiated newborns.
Additional files
Additional file 1: Figure S1. Fas-ligand (FasL) (A) and Interleukin-6 (IL-6)
(B) levels in the cerebrospinal fluid (CSF) correlate inversely with Apgar
scores at 10 min (rs = − 0.577 and − 0.622, respectively. rs = Spearman rank
correlation coefficient) (both p < 0.0001). (TIF 119 kb)
Additional file 2: Table S1. Soluble Fas receptor (sFas) levels in 26
asphyxia patients and 20 controls. (DOCX 15 kb)
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